Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

70.00GBp
7 Dec 2018
Change (% chg)

1.00 (+1.45%)
Prev Close
69.00
Open
69.25
Day's High
70.55
Day's Low
68.65
Volume
843,373
Avg. Vol
1,197,431
52-wk High
127.22
52-wk Low
65.85

Chart for

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.41
Market Cap(Mil.): £705.16
Shares Outstanding(Mil.): 679.34
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 31.13 33.63
EPS (TTM): -- -- --
ROI: -- 15.55 15.02
ROE: -- 16.92 16.60

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

26 Nov 2018

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

26 Nov 2018

UPDATE 2-Vectura drops severe asthma treatment after poor trial results

* Shares fall more than 10 percent (Adds CEO, analyst comment, share movement)

26 Nov 2018

Vectura to stop developing asthma treatment after late-stage failure

Nov 26 British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.

26 Nov 2018

UPDATE 1-Vectura reviewing drug stockpiles as no-deal Brexit looms

Sept 11 British drugmaker Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its mitigation plan for a "no-deal" Brexit and warned on Tuesday of a potential disruption to supply chains and higher costs.

11 Sep 2018

Vectura reviewing drug stockpiles as no-deal Brexit looms

Sept 11 Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its plan for a "no-deal" Brexit, the British drugmaker said on Tuesday, and warned of a potential disruption to supply chains and higher costs.

11 Sep 2018

Earnings vs. Estimates